低危主动脉瓣狭窄患者无缝合瓣膜植入术后永久起搏器植入的发生率、预测因素及预后价值
研究纳入2013至2019年2个中心400例低危(EuroSCORE II < 4%)无既往起搏器、接受Perceval无缝合主动脉瓣置换术的患者,36例(9%)术后需植入永久起搏器,中位植入时间7.5天,基线右束支传导阻滞是独立预测因素(OR 2.60),中位随访3.4年永久起搏器与死亡及心衰再住院无显著差异。
要点
- 低危患者无缝合瓣膜术后永久起搏器植入率9%(36/400),中位时间7.5天。
- 基线右束支传导阻滞为独立预测因素(OR 2.60,95%CI 1.15-5.81,P=0.022)。
- 中位随访3.4年,起搏器组与无起搏器组死亡及心衰再住院无显著差异。
核心结论
- 约十分之一低危主动脉瓣狭窄患者接受Perceval无缝合瓣膜置换术后需植入永久起搏器。
- 基线右束支传导阻滞使术后起搏器植入风险增加近3倍。
- 永久起搏器植入与3年随访临床事件风险升高无关。
研究设计与样本
- 2013至2019年2个中心连续纳入400例低危(EuroSCORE II < 4%)无既往起搏器、接受Perceval无缝合主动脉瓣置换术的患者。
- 收集基线、临床及心电图参数、手术特征和随访数据。
主要发现
- 36例(9%)患者术后需植入永久起搏器,中位植入时间7.5(4.5-10.5)天。
- 高龄和既往右束支传导阻滞与起搏器风险增加相关(P < 0.05),仅基线右束支传导阻滞为独立预测因素(OR 2.60,95%CI 1.15-5.81,P = 0.022)。
- 中位随访3.4(2.3-4.5)年,起搏器组与无起搏器组死亡率分别为36%与22%(P = 0.105),心衰再住院分别为25%与21%(P = 0.839),均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sutureless aortic valve replacement (SU-SAVR) has been associated with higher rates of permanent pacemaker (PPM) compared with conventionally implanted aortic bioprostheses. The purpose of this study was to determine the incidence, predictors and mid-term prognostic impact of PPM after Perceval (Livanova, London, UK) SU-SAVR in low-risk patients. METHODS: A total of 400 consecutive low-risk (EuroSCORE II < 4%) patients without prior pacemaker who underwent surgical aortic valve replacement with the Perceval prosthesis from 2013 to 2019 in 2 centres were included. Baseline, clinical and electrocardiographic parameters, procedural characteristics and follow-up data were collected. RESULTS: PPM was required in 36 (9%) patients after SU-SAVR, with a median time between the procedure and PPM implantation of 7.5 (4.5-10.5) days. Older age and prior right bundle branch block (RBBB) were associated with an increased risk of PPM (P < 0.05 for all), but only baseline RBBB was found to be an independent predictor of new PPM requirement (odds ratio: 2.60, 95% confidence interval: 1.15-5.81; P = 0.022). At a median follow-up of 3.4 (2.3-4.5) years, there were no differences between groups in mortality (PPM: 36%, no PPM: 22%, P = 0.105) or heart failure rehospitalization (PPM: 25%, no PPM: 21%, P = 0.839). CONCLUSIONS: About 1 out of 10 low-risk patients with aortic stenosis undergoing SU-SAVR with the Perceval prosthesis required PPM implantation. Prior RBBB determined an increased risk (close to 3-fold) of PPM following the procedure. PPM was not associated with a higher risk of clinical events at 3-year follow-up.
引用
- Vilalta V, Cediel G, Mohammadi S, et al. Incidence, predictors and prognostic value of permanent pacemaker implantation following sutureless valve implantation in low-risk aortic stenosis patients. Eur J Cardiothorac Surg. 2022. PMID: 35639725. doi:10.1093/ejcts/ezac307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。